Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2024 Earnings Call Transcript August 1, 2024Regeneron Pharmaceuticals, Inc. beats earnings expectations.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 267,032 | $280,658,643 | +35% | 0.12% |
| 2. | D E Shaw D. E. Shaw | 254,415 | $267,397,797 | +11% | 0.25% |
| 3. | AQR Capital Management Cliff Asness | 189,291 | $198,571,644 | +4% | 0.3% |
| 4. | Renaissance Technologies Jim Simons | 185,162 | $194,610,817 | +12% | 0.33% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 181,897 | $191,179,204 | +7% | 1.82% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | 23,880,537 | 2017-08-25 | Filing | ||
| $485.99 | 2,681 | 23,877,980 | 2017-08-25 | Filing | ||
| $485.28 | 5,723 | 23,875,299 | 2017-08-25 | Filing | ||
| $484.21 | 2,000 | 23,869,576 | 2017-08-25 | Filing | ||
| $482.87 | 4,485 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1,170.00 | 756 | Director | 1,382 | 2024-08-15 | Filing | |
| $1,161.32 | 100 | Director | 2,172 | 2024-08-15 | Filing | |
| $1,160.45 | 234 | Director | 2,272 | 2024-08-15 | Filing | |
| $1,159.56 | 5,352 | Director | 2,506 | 2024-08-15 | Filing | |
| $1,158.02 | 212 | Director | 7,858 | 2024-08-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,317,415 | $9,061,682,469 | 0.69% | |
| 2. | 8,838,285 | $7,762,577,333 | 0.16% | |
| 3. | 8,629,707 | $7,579,385,538 | 0.19% | |
| 4. | 7,226,769 | $6,347,199,734 | 0.67% | |
| 5. | 5,130,485 | $4,506,070,906 | 0.8% |
News See All
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc.
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and understand the reasons behind...
23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $9.55 EPS, expectations were $10.17. Regeneron Pharmaceuticals, Inc.
11 Oversold Growth Stocks to Buy Right Now
In this article, we will take a look at the 11 oversold growth stocks to buy right now.
5 Biggest Biotechnology Companies in the World
Argenx SE (NASDAQ:ARGX), based in the Netherlands, is one of the biggest biotechnology companies in the world known for its innovative immunology solutions.
5 Biotech Stocks with Huge Potential
In this article, we will take a look at the 5 biotech stocks with huge potential.
20 Fastest Growing Biotech Companies in the US
In this article, we will be taking a look at the 20 fastest growing biotech companies in the US.
16 Most Advanced Countries in Medicine
In this article, we list and discuss the 16 Most Advanced Countries in Medicine.
Billionaire Hedge Funds
